Vanguard Mega Cap Value ETF

Vanguard Mega Cap Value ETF (MGV) is an index fund that tracks the CRSP U.S. Mega Cap Value Index. It holds about 120 of the largest US value stocks. As of August 31, 2026, its biggest positions were Micron Technology, JPMorgan Chase and Berkshire Hathaway. It costs 0.07% a year, below the 0.14% average for similar funds. Vanguard Value ETF (VTV), which shares 71% of MGV's holdings, costs less at 0.04%.

• Over the year to Nov 2, 2026, MGV returned +25.8%, 2nd of 9 among similar funds.
• Its 5-year annualized return was +12.8% and its 10-year +13.5%.
• In the 2020 COVID crash it fell 35% and regained its old high 8.4 months after the low.
• Its worst full calendar year was 2008 (-35.6%); its best was 2013 (+32.2%).
• The deepest fall in its price history was 55.9% (Dec 27, 2007 to Mar 5, 2009), recovered by Oct 5, 2012.

As of Aug 31, 2026, the fund held 121 securities; the ten largest made up 28.53% of assets.

By sector

• Over the three months to Aug 31, 2026, investors added a net $465.9M (creations minus redemptions, per the N-PORT report).
• Monthly total returns reported for that quarter: +4.20%, -0.20%, +2.43%.

MGV is the exchange-traded share class of Vanguard Mega Cap Value Index Fund. It tracks the CRSP U.S. Mega Cap Value Index. The index starts with the very largest US companies, the ones that make up the top 70% of the investable US stock market by market value. The index provider calls these mega-cap stocks. From that group it keeps the companies it classifies as value stocks. Value stocks are shares that trade at lower prices relative to their earnings, assets or other measures than the market as a whole.

The index weights companies by float-adjusted market value. Bigger companies get bigger weights, and only shares available to public investors count. Vanguard copies the index directly, holding nearly every stock in about the same proportion. As of August 31, 2026, the fund held 121 stocks, and the top 10 made up 28.5% of assets. Micron Technology was the largest position at 5.0%, followed by JPMorgan Chase at 4.4%. Financials made up 23.5% of the fund, health care 16.5% and technology 14.6%.

Trading inside the fund is light. Portfolio turnover was 8%, according to the prospectus. The fund also held a few futures and swap contracts, each a tiny fraction of 1% of assets. Shares trade on NYSE Arca at market prices, which can differ slightly from the value of the fund's holdings. Only large firms called authorized participants can create or redeem shares directly with the fund.

• MGV charges 0.07% a year, versus an average of 0.14% for the similar funds below (5th of 9, cheapest first).
• Of that, 0.06% is the management fee; the rest covers other fund expenses.
• Using the prospectus's standard example, $10,000 invested would cost about $7 in the first year and $90 over 10 years (assuming a 5% annual return).

It offers low-cost, broad exposure to about 120 of the largest US companies, with a tilt toward value sectors such as financials and health care.

MGV could serve as the large-company stock core of a portfolio, though it has a value tilt. It has suffered deep drops. The fund launched in December 2007 and fell 55.9% by March 2009. It lost 35.6% in 2008 and took about 43 months to recover, until October 2012. In the 2020 COVID crash it fell 35% in five weeks and recovered by December 2020, about 8.4 months later. In 2022 it fell 16.5% at its worst but ended the year down just 1.23%. Someone forced to sell shares during a slump like 2008 would lock in heavy losses. The fund yielded 1.82% as of October 27, 2026, with dividends paid quarterly. It costs 0.07% a year, or $90 over 10 years on $10,000 in the SEC's standard example. Past results don't predict the future, and a plan should look at the whole portfolio, not one fund.

Matched by holdings overlap from the latest N-PORT reports.